Archives of Neuroscience

Published by: Kowsar

Recombinant Tissue Plasminogen Activator Administration in Patients With Cerebrovascular Accident; A Case Series

Hosein Delavar Kasmaei 1 , Alireza Baratloo 2 , * , Zahra Nasiri 1 , Maryam Soleymani 1 and Maryam Oraee Yazdani 3
Authors Information
1 Department of Neurology, Shohadaye Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 Department of Emergency Medicine, Shohadaye Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
3 Department of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • Archives of Neuroscience: April 01, 2015, 2 (2); e23315
  • Published Online: April 1, 2015
  • Article Type: Research Article
  • Received: September 7, 2014
  • Revised: October 8, 2014
  • Accepted: October 15, 2014
  • DOI: 10.5812/archneurosci.23315

To Cite: Delavar Kasmaei H, Baratloo A, Nasiri Z, Soleymani M, Oraee Yazdani M. Recombinant Tissue Plasminogen Activator Administration in Patients With Cerebrovascular Accident; A Case Series, Arch Neurosci. 2015 ; 2(2):e23315. doi: 10.5812/archneurosci.23315.

Copyright © 2015, Tehran University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet. 2008; 371(9624): 1612-23[DOI][PubMed]
  • 2. Durai Pandian J, Padma V, Vijaya P, Sylaja PN, Murthy JM. Stroke and thrombolysis in developing countries. Int J Stroke. 2007; 2(1): 17-26[DOI][PubMed]
  • 3. Ghandehari K. Barriers of thrombolysis therapy in developing countries. Stroke Res Treat. 2011; 2011: 686797[DOI][PubMed]
  • 4. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol. 2009; 8(4): 355-69[DOI][PubMed]
  • 5. Tosta ED, Rebello LC, Almeida SS, Neiva MS. Treatment of ischemic stroke with r-tPA: implementation challenges in a tertiary hospital in Brazil. Arq Neuropsiquiatr. 2014; 72(5): 368-72[PubMed]
  • 6. Ranklev E, Fletcher R. Anaesthetic management of the malignant hyperthermia susceptible parturient. Can J Anaesth. 1987; 34(1): 106[DOI][PubMed]
  • 7. Kent DM, Price LL, Ringleb P, Hill MD, Selker HP. Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke: a pooled analysis of randomized clinical trials. Stroke. 2005; 36(1): 62-5[DOI][PubMed]
  • 8. Lai CC, Hu CJ. A left MCA territory infarction during intravenous recombinant tissue plasminogen activator therapy for right MCA territory ischaemic stroke. Emerg Med J. 2006; 23(2)[DOI][PubMed]
  • 9. Li Y, Margraf J, Kluck B, Jenny D, Castaldo J. Thrombolytic therapy for ischemic stroke secondary to paradoxical embolism in pregnancy: a case report and literature review. Neurologist. 2012; 18(1): 44-8[DOI][PubMed]
  • 10. Jauch EC, Saver JL, Adams HP, Jr., Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013; 44(3): 870-947[DOI][PubMed]
  • 11. Albers GW. Expanding the window for thrombolytic therapy in acute stroke. The potential role of acute MRI for patient selection. Stroke. 1999; 30(10): 2230-7[PubMed]
  • 12. Arakawa S, Wright PM, Koga M, Phan TG, Reutens DC, Lim I, et al. Ischemic thresholds for gray and white matter: a diffusion and perfusion magnetic resonance study. Stroke. 2006; 37(5): 1211-6[DOI][PubMed]
  • 13. Gladstone DJ, Black SE. Update on intravenous tissue plasminogen activator for acute stroke: from clinical trials to clinical practice. CMAJ. 2001; 165(3): 311-7[PubMed]
  • 14. Graham GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke. 2003; 34(12): 2847-50[DOI][PubMed]
  • 15. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000; 283(9): 1145-50[PubMed]
  • 16. Mullen MT, Pisapia JM, Tilwa S, Messe SR, Stein SC. Systematic review of outcome after ischemic stroke due to anterior circulation occlusion treated with intravenous, intra-arterial, or combined intravenous+intra-arterial thrombolysis. Stroke. 2012; 43(9): 2350-5[DOI][PubMed]
  • 17. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010; 375(9727): 1695-703[DOI][PubMed]
  • 18. Ramaiah SS, Yan B. Low-dose tissue plasminogen activator and standard-dose tissue plasminogen activator in acute ischemic stroke in Asian populations: a review. Cerebrovasc Dis. 2013; 36(3): 161-6[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments